Loading...
Inebilizumab: First Approval
Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of a range of autoimmune diseases associated with CD19-expressing B cells. Inebilizumab targets and depletes CD19-expressing B cells through antibody-depe...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7387876/ https://ncbi.nlm.nih.gov/pubmed/32729016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01370-4 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|